Although the overall cure rate of acute lymphoblastic leukemia (ALL) in children is about 80
percent, affected adults fare less well. This review considers recent advances in the …

Acute lymphoblastic leukaemia, a malignant disorder of lymphoid progenitor cells, affects
both children and adults, with peak prevalence between the ages of 2 and 5 years. Steady …

… C. Zhou et al. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET
Fusion–Positive NSCLC C. Zhou et al. … Data were modified from Pui and Evans 10 to …

Background Prophylactic cranial irradiation has been a standard treatment in children with
acute lymphoblastic leukemia (ALL) who are at high risk for central nervous system (CNS) …

The classification of myeloid neoplasms and acute leukemias was last updated in 2016
within a collaboration between the World Health Organization (WHO), the Society for …

Abstract Treatment of pediatric acute lymphoblastic leukemia (ALL) is based on the concept
of tailoring the intensity of therapy to a patient's risk of relapse. To determine whether gene …

Chromosomal aberrations are a hallmark of acute lymphoblastic leukaemia (ALL) but alone
fail to induce leukaemia. To identify cooperating oncogenic lesions, we performed a genome…

Early T-cell precursor acute lymphoblastic leukaemia (ETP ALL) is an aggressive malignancy
of unknown genetic basis. We performed whole-genome sequencing of 12 ETP ALL cases …

Background Despite best current therapy, up to 20% of pediatric patients with acute lymphoblastic
leukemia (ALL) have a relapse. Recent genomewide analyses have identified a high …

Background Philadelphia chromosome–like acute lymphoblastic leukemia (Ph-like ALL) is
characterized by a gene-expression profile similar to that of BCR–ABL1–positive ALL, …